SCHILKE TOBIN (CFO) received a stock award from REVANCE THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 8/15/2023ACC: 0001479290-23-000099
Officer· CFO
Since Nov 2018
+11.40K
Net shares
Net buyer
$212.1K
Total sold
0
Open market trades
0B · 0S
2
Total transactions
22.62K acquired · 11.21K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+22.62K
Price / share
—
Trade value
—
% of position
28.3%
8/11/2023
79.90K→102.52K
Common Stock
Direct
Shares
−11.21K
Price / share
$18.91
Trade value
$212.08K
% of position
10.9%
8/11/2023
102.52K→91.30K
Total
Net shares
+11.40K
Net value
-$212.08K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/11/2023 | A · Award | +22.62K | — | — | 28.3% | 79.90K | 102.52K |
| Common Stock Direct | 8/11/2023 | F · Tax Withholding | −11.21K | $18.91 | $212.08K | 10.9% | 102.52K | 91.30K |
| Total | +11.40K | -$212.08K | ||||||
Derivative Transactions0
No derivative transactions reported